Tandem Diabetes Care [TNDM] vs Conmed [CNMD] Detailed Stock Comparison
Tandem Diabetes Care
NASDAQ
Loading...
Conmed
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Tandem Diabetes Care wins in 4 metrics, Conmed wins in 14 metrics, with 0 ties. Conmed appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Tandem Diabetes Care | Conmed | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -7.27 | 15.40 | Tandem Diabetes Care |
| Price-to-Book Ratio | 5.52 | 1.68 | Conmed |
| Debt-to-Equity Ratio | 340.56 | 87.93 | Conmed |
| PEG Ratio | -0.11 | -0.53 | Conmed |
| EV/EBITDA | -11.52 | 11.52 | Tandem Diabetes Care |
| Profit Margin (TTM) | -20.51% | 8.31% | Conmed |
| Operating Margin (TTM) | -13.24% | 10.62% | Conmed |
| EBITDA Margin (TTM) | N/A | 10.62% | N/A |
| Return on Equity | -111.92% | 11.69% | Conmed |
| Return on Assets (TTM) | -6.41% | 4.03% | Conmed |
| Free Cash Flow (TTM) | $4.99M | $153.88M | Conmed |
| Dividend Yield | N/A | 1.15% | N/A |
| 1-Year Return | -75.22% | -26.24% | Conmed |
| Price-to-Sales Ratio (TTM) | 0.73 | 1.27 | Tandem Diabetes Care |
| Enterprise Value | $874.38M | $2.53B | Conmed |
| EV/Revenue Ratio | 0.87 | 1.91 | Tandem Diabetes Care |
| Gross Profit Margin (TTM) | 52.29% | 55.01% | Conmed |
| Revenue per Share (TTM) | $15 | $43 | Conmed |
| Earnings per Share (Diluted) | $-3.08 | $3.54 | Conmed |
| Beta (Stock Volatility) | 1.47 | 1.17 | Conmed |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Tandem Diabetes Care vs Conmed Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Tandem Diabetes Care | 7.92% | 3.66% | -24.47% | -48.96% | -64.35% | -69.17% |
| Conmed | 5.13% | 0.82% | 10.93% | -7.56% | -13.19% | -21.20% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Tandem Diabetes Care | -75.22% | -76.33% | -90.22% | -90.56% | -94.94% | -94.94% |
| Conmed | -26.24% | -42.25% | -38.83% | -1.30% | 177.71% | 90.76% |
Performance & Financial Health Analysis: Tandem Diabetes Care vs Conmed
| Metric | TNDM | CNMD |
|---|---|---|
| Market Information | ||
| Market Cap | $735.83M | $1.69B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 3,752,020 | 574,807 |
| 90 Day Avg. Volume | 2,384,093 | 539,906 |
| Last Close | $11.93 | $55.79 |
| 52 Week Range | $9.98 - $47.60 | $46.00 - $78.19 |
| % from 52W High | -74.95% | -28.65% |
| All-Time High | $302.50 (Jan 13, 2014) | $159.11 (Nov 01, 2021) |
| % from All-Time High | -96.06% | -64.94% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.09% | 0.03% |
| Quarterly Earnings Growth | N/A | -0.29% |
| Financial Health | ||
| Profit Margin (TTM) | -0.21% | 0.08% |
| Operating Margin (TTM) | -0.13% | 0.11% |
| Return on Equity (TTM) | -1.12% | 0.12% |
| Debt to Equity (MRQ) | 340.56 | 87.93 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.97 | $32.41 |
| Cash per Share (MRQ) | $4.67 | $1.10 |
| Operating Cash Flow (TTM) | $9.72M | $165.21M |
| Levered Free Cash Flow (TTM) | $31.96M | $163.74M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.15% |
| Last 12-Month Dividend | N/A | $0.60 |
Valuation & Enterprise Metrics Analysis: Tandem Diabetes Care vs Conmed
| Metric | TNDM | CNMD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -7.27 | 15.40 |
| Forward P/E | -9.00 | 11.26 |
| PEG Ratio | -0.11 | -0.53 |
| Price to Sales (TTM) | 0.73 | 1.27 |
| Price to Book (MRQ) | 5.52 | 1.68 |
| Market Capitalization | ||
| Market Capitalization | $735.83M | $1.69B |
| Enterprise Value | $874.38M | $2.53B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.87 | 1.91 |
| Enterprise to EBITDA | -11.52 | 11.52 |
| Risk & Other Metrics | ||
| Beta | 1.47 | 1.17 |
| Book Value per Share (MRQ) | $1.97 | $32.41 |
Financial Statements Comparison: Tandem Diabetes Care vs Conmed
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TNDM | CNMD |
|---|---|---|
| Revenue/Sales | $234.42M | $321.26M |
| Cost of Goods Sold | $116.02M | $143.50M |
| Gross Profit | $118.41M | $177.75M |
| Research & Development | $125.43M | $12.95M |
| Operating Income (EBIT) | $-120.88M | $15.96M |
| EBITDA | $-116.42M | $34.21M |
| Pre-Tax Income | $-122.09M | $7.67M |
| Income Tax | $8.47M | $1.64M |
| Net Income (Profit) | $-130.56M | $6.04M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TNDM | CNMD |
|---|---|---|
| Cash & Equivalents | $53.57M | $35.49M |
| Total Current Assets | $663.44M | $639.00M |
| Total Current Liabilities | $288.18M | $283.15M |
| Long-Term Debt | $431.75M | $891.44M |
| Total Shareholders Equity | $155.29M | $977.64M |
| Retained Earnings | $-1.18B | $560.13M |
| Property, Plant & Equipment | $79.22M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TNDM | CNMD |
|---|---|---|
| Operating Cash Flow | $-6.71M | $49.72M |
| Capital Expenditures | $-6.21M | $-3.78M |
| Free Cash Flow | $-15.70M | $37.76M |
| Debt Repayment | $-40.76M | $-180.59M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | TNDM | CNMD |
|---|---|---|
| Shares Short | 8.75M | 2.10M |
| Short Ratio | 4.75 | 4.31 |
| Short % of Float | 0.18% | 0.09% |
| Average Daily Volume (10 Day) | 3,752,020 | 574,807 |
| Average Daily Volume (90 Day) | 2,384,093 | 539,906 |
| Shares Outstanding | 66.26M | 30.90M |
| Float Shares | 61.84M | 30.68M |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 1.21% | 1.15% |
Dividend Analysis & Yield Comparison: Tandem Diabetes Care vs Conmed
| Metric | TNDM | CNMD |
|---|---|---|
| Last 12-Month Dividend | N/A | $0.60 |
| Last 12-Month Dividend Yield | N/A | 1.15% |
| 3-Year Avg Annual Dividend | N/A | $0.73 |
| 3-Year Avg Dividend Yield | N/A | 0.24% |
| 3-Year Total Dividends | N/A | $2.20 |
| Ex-Dividend Date | N/A | Mar 14, 2025 |